Warner Bros shareholders back $110bn Paramount merger

Warner Bros Discovery shareholders approved the proposed $110 billion merger with Paramount Skydance, advancing a deal that could close in Q3 this year. However, investors voted against executive compensation tied to the transaction, with CEO David Zaslav eligible for up to $887 million if the sale completes. Regulatory scrutiny remains the main hurdle, with the DOJ already issuing subpoenas and authorities in Washington, London and Europe expected to assess competition concerns.

Analysis

The market is moving from “deal certainty” to “deal friction,” and that shift is where the tradeable edge sits. Shareholder approval removes one overhang for WBD, but it does not eliminate the real gating factor: antitrust review with a higher probability of delay than outright blockage. That matters because the economics of the transaction are increasingly time-dependent; every extra quarter pushes out synergies, prolongs balance-sheet uncertainty, and keeps WBD in a hostage-to-close regime where the stock can underperform even if the deal ultimately happens.

The second-order effect is on the bidders and on the broader streaming stack. Paramount is effectively making a strategic all-in bet on consolidation to regain scale, but the market may start pricing in the cost of that bet: integration risk, management distraction, and a potential need to re-cut terms if regulators demand remedies. For NFLX, the direct read-through is modestly negative not because it loses a specific asset today, but because a successful merger would increase the odds of an industry-wide response toward bundling, sports/linear re-aggregation, and stronger bargaining leverage from the remaining large studios—structures that can slow subscriber acquisition efficiency and raise content input costs over the next 12-24 months.

The governance vote against pay is not cosmetic; it increases the probability that any delay becomes politically toxic, especially if regulators request concessions. That raises tail risk for WBD holders: if approvals stretch into late Q3 or Q4, the market may begin to discount break risk, competing bids, or a price re-trade. Contrarian view: the consensus is probably overestimating the immediacy of DOJ action and underestimating European remedy requirements; however, it may also be underestimating how much of the deal risk is already in WBD’s price, making the stock less attractive on a standalone basis but more attractive for event-driven spreads than outright directional longs.

Key Decisions for Investors

• Long WBD / short a media basket or NFLX, structured as an event-driven spread for the next 6-12 weeks; thesis is that WBD retains deal optionality while NFLX faces modest multiple pressure from potential post-merger industry consolidation and bundling pressure.
• Sell WBD downside via put spread into any strength over the next 30-45 days; implieds should stay supported, but the most likely near-term outcome is delay rather than collapse, making premium sale attractive if strike placement leaves room for a regulatory drawdown.
• Buy WBD merger-arb exposure only if it trades at a discount that implies >50% probability of a 1-2 quarter delay; the risk/reward improves if the market starts pricing break risk faster than the actual antitrust process deteriorates.
• Avoid outright short NFLX on headline risk alone; if anything, use it as a hedge leg against long WBD because the real negative for NFLX is a structurally more consolidated content supply chain, which plays out over quarters rather than days.
• If the stock reacts positively on shareholder approval, fade the move into regulatory milestones rather than chasing; the next catalyst is not approval but remedy requests, which can reprice the deal spread sharply within 2-8 weeks.